XTLB Valuation

X T L Biopharmaceuticals Ltd

Add to Watchlist

Advanced Chart

1.830

+0.08(4.571%)1D

Overview
Forecast
Valuation
Earnings

XTLB Relative Valuation

XTLB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XTLB is overvalued; if below, it's undervalued.

Historical Valuation

X T L Biopharmaceuticals Ltd (XTLB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.05 is considered Undervalued compared with the five-year average of 9.91. The fair price of X T L Biopharmaceuticals Ltd (XTLB) is between 68.64 to 72.37 according to relative valuation methord. Compared to the current price of 1.75 USD , X T L Biopharmaceuticals Ltd is Undervalued By 97.45%.

Relative Value

Fair Zone

68.64-72.37

Current Price：1.75

97.45%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

291.11

P/B

Median3y

277.33

Median5y

318.11

-9.90

FCF Yield

Median3y

-3.80

Median5y

-3.30

Competitors Valuation Multiple

The average P/S ratio for XTLB's competitors is 8.72, providing a benchmark for relative valuation. X T L Biopharmaceuticals Ltd Corp (XTLB) exhibits a P/S ratio of 0.05, which is -99.41% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

XTLB.O

X T L Biopharmaceuticals Ltd

0.05

Average P/S: 8.72

1.54B